Treatment Set TS329894 is a Intradermal; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Antigen Laboratories, Inc.. The primary component is Alternaria Alternata; Felis Catus Hair; Dermatophagoides Pteronyssinus; Platanus Occidentalis Pollen; Morus Rubra Pollen; Juniperus Virginiana Pollen; Ambrosia Artemisiifolia Pollen.
| Product ID | 49288-0690_89f9e682-acd9-4cc7-982d-c32f69b33b07 |
| NDC | 49288-0690 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Treatment Set TS329894 |
| Generic Name | Treatment Set Ts329894 |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRADERMAL; SUBCUTANEOUS |
| Marketing Start Date | 1986-10-31 |
| Marketing Category | BLA / BLA |
| Application Number | BLA102223 |
| Labeler Name | Antigen Laboratories, Inc. |
| Substance Name | ALTERNARIA ALTERNATA; FELIS CATUS HAIR; DERMATOPHAGOIDES PTERONYSSINUS; PLATANUS OCCIDENTALIS POLLEN; MORUS RUBRA POLLEN; JUNIPERUS VIRGINIANA POLLEN; AMBROSIA ARTEMISIIFOLIA POLLEN |
| Active Ingredient Strength | 0 g/mL; [BAU]/mL; [AU]/mL; g/mL; g/mL; g/mL; [AU]/mL |
| Pharm Classes | Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Standardized Animal Hair Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Dander [CS],Allergens [CS],Salivary Proteins and Peptides [CS],Standardized Insect Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Antigens, Dermatophagoides [CS],Insect Proteins [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS] |
| NDC Exclude Flag | E |
| Listing Certified Through | 2017-12-31 |
| Marketing Start Date | 1986-10-31 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA102223 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1986-10-31 |
| Inactivation Date | 2019-10-21 |
| Ingredient | Strength |
|---|---|
| ALTERNARIA ALTERNATA | .00017 g/mL |